AAREYDRUGS.NSAAREYDRUGS.NSNSE
Loading
EBITDA Over TimeContracting
Percentile Rank47
3Y CAGR-9.1%
5Y CAGR-7.6%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
-9.1%/yr
vs +0.8%/yr prior
5Y CAGR
-7.6%/yr
Consistent
Acceleration
-9.8pp
Decelerating
Percentile
P47
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$78.61M-34.8%
2025$120.64M+5.7%
2024$114.16M+9.2%
2023$104.50M-25.7%
2022$140.63M+20.6%
2021$116.65M+60.9%
2020$72.48M-28.5%
2019$101.38M+23.0%
2018$82.40M-16.1%
2017$98.18M-